Phase II and III trials

Clinical Lung Cancer

Volumn 2, Issue 1, 2000, Pages 21-22

  Fisher, M D ^a   D'Orazio, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE;

ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BRAIN METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0034463741     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1525-7304(11)70620-9     Document Type: Article

References (7)

1. An update on North American randomized studies in non-small cell lung cancer
2. New agents in the management of advanced non-small cell lung cancer
3. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): An update of a Southwest Oncology Group study (SWOG-9308)
4. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
5. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated tumors
6. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Group trial
7. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)